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 ABSTRACT 38 
Cystic fibrosis (CF) is a genetic disorder associated with vascular endothelial 39 
dysfunction. Nitric oxide (NO) plays a major role in maintaining vascular function and 40 
tetrahydrobiopterin (BH4) is a critical determinant of NO bioavailability. Thus, the 41 
purpose of this study was to investigate the effects of oral administration of BH4 on 42 
endothelial function in patients with CF.    43 
Methods: 29 patients with CF (18 ± 8 yrs old) and 29 healthy matched controls were 44 
recruited. Patients with CF participated in a randomized trial where they received a 5 45 
mg/kg dose of oral BH4 (BH4-5; n=17) or a 20 mg/kg dose of oral BH4 (BH4-20; n=12). 46 
On a separate visit, a subset of patients from each group were retested following a 47 
placebo (PLC, n=9). Brachial artery flow-mediated dilation (FMD) was used to evaluate 48 
vascular endothelial function and a plasma sample was obtained before and 3 h after 49 
treatment.  Cultured endothelial cells were treated with plasma to assess NO 50 
bioavailability.   51 
Results: Baseline FMD was lower in patients compared to controls (5.7 ± 3.4% vs. 8.4 52 
± 3.5% respectively, p = 0.005). No change in FMD was observed following PLC or BH4-53 
5 (∆FMD: -0.8 ± 0.0% and -0.5 ± 2.5%; p=0.273 and 0.132, respectively). Treatment 54 
with BH4-20, however, resulted in significant improvements in FMD (∆FMD: 1.1 ± 1.4%) 55 
compared to BH4-5 (p=0.023) and PLC (p=0.017). Moreover, BH4-20 significantly 56 
decreased endothelial cell superoxide production and increased NO production. 57 
Conclusion: These data suggest that a single oral dose of BH4 at 20 mg/kg improves 58 
vascular endothelial function in patients with CF, likely via increased endothelial NOS 59 
Downloaded from www.physiology.org/journal/jappl by ${individualUser.givenNames} ${individualUser.surname} (158.093.006.013) on November 16, 2018.
 Copyright © 2018, Journal of Applied Physiology. All rights reserved. 
Page | 3 
 
coupling. These findings support the hypothesis that loss of BH4 bioactivity contributes, 60 
in part, to endothelial dysfunction in patients with CF. 61 
New & Noteworthy 62 
For the first time, the present study documents that a single dose of oral BH4 can 63 
improve vascular endothelial function in patients with CF, and our in vitro data suggests 64 
this is via decreasing uncoupled NO. These data provide insight into the important role 65 
of BH4 bioactivity on vascular dysfunction and provide the foundation for further 66 
investigation into the chronic effects of BH4 treatment in patients with CF. 67 
 68 
  69 
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INTRODUCTION 70 
Cystic fibrosis (CF), the most common autosomal recessive disorder among 71 
Caucasians, is caused by mutation of the cystic fibrosis transmembrane conductance 72 
regulator (CFTR) gene (27). The pathological consequences of this CFTR mutation in 73 
CF leads to multiple systemic complications including respiratory, gastrointestinal, 74 
endocrine, and musculoskeletal manifestations; all together contributing to early 75 
mortality (11, 31).       76 
CFTR is expressed in the vascular endothelium (34).  Therefore, it is reasonable 77 
to believe a mutant CFTR protein within the endothelium contributes to the existence of 78 
both micro- (30) and conduit- (24) vascular endothelial dysfunction in patients with CF.  79 
Endothelial dysfunction impairs adequate nutrient supply to active tissues in patients 80 
with CF (35), which may contribute to exercise intolerance, an independent predictor of 81 
mortality in this patient population (22). The underlying mechanism of endothelial 82 
dysfunction in CF; however, has yet to be elucidated.   83 
Nitric oxide (NO), a potent endothelium-derived vasodilator produced by NO 84 
synthase (NOS), plays a major role in maintaining normal vascular endothelial function 85 
(16). Tetrahydrobiopterin (BH4) is an essential cofactor for eNOS function and is a 86 
critical regulator of NO production. Consequently, when BH4 bioactivity is reduced, 87 
eNOS can become uncoupled and results in production of superoxide rather than NO 88 
(2). Indeed, BH4 deficiency reduces NO bioavailability and contributes to a decrease in 89 
endothelial function in various pathological conditions including pulmonary hypertension 90 
(25), diabetes (14), and smoking (13). Conversely, ingestion of BH4 has been show to 91 
improve flow-mediated dilation (FMD), a non-invasive bioassay of NO bioavailability and 92 
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vascular endothelial function (10) in older adults (6), chronic smokers (32) and patients 93 
with rheumatoid arthritis (19). Whether or not ingestion of BH4 improves endothelial 94 
function in patients with CF has yet to be investigated.   95 
The vascular effects following oral administration of BH4 are complex and appear 96 
to be dose dependent (5, 23). Enzymatic reactivity of BH4 and the subsequent influence 97 
on NO-dependent endothelial vasodilation are highly sensitive to the surrounding 98 
biochemical conditions, including overall redox state (33). Thus, identifying an 99 
appropriate dose of BH4 that can effectively increase NO production and improve 100 
vascular endothelial function is of great interest in CF, a population that exhibits 101 
elevated oxidative stress and vascular dysfunction(9). Accordingly, this proof of concept 102 
study sought to test the hypothesis that oral administration of a high dose of BH4 in 103 
patients with CF would improve vascular endothelial function, compared to a low BH4 104 
dose or placebo. 105 
  106 
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METHODS 107 
Participants. Patients with CF, aged 8-39 years old, were enrolled if they had a clinical 108 
diagnosis of CF based on positive sweat tests and genotype analysis. Patients were 109 
excluded if they 1) had a forced expiratory volume in 1 second (FEV1) < 50 % predicted, 110 
2) had a resting oxygen saturation (SpO2) <85%, 3) self-reported to be a smoker, 4) 111 
were diagnosed with pulmonary hypertension, 5) were pregnant or nursing at the time of 112 
the investigation, 6) had a clinical diagnosis of cardiovascular disease, hypertension, or 113 
CF related diabetes, or 7) were prescribed any vaso-active medications (e.g. nitrates, 114 
beta blockers, ACE inhibitors, etc.). Demographically-matched healthy individuals were 115 
recruited as controls (CON) to compare basal vascular function to the patients. All 116 
participants and parents of minors provided written and verbal informed consent/assent 117 
prior to participation. All study protocols were carried out according to Declaration of 118 
Helsinki and not only approved by the Augusta University Institutional Review Board, 119 
but also registered at Clinicaltrials.gov (NCT01772758).   120 
Experimental Design. This proof of concept study was designed based on our pilot 121 
study in 5 CF patients that tested the safety and feasibility of a low dose (5 mg/kg) of 122 
oral BH4 and found no BH4-induced change in endothelial function. Based on this 123 
preliminary result, we included a higher dose BH4 group (20 mg/kg) for comparison. 124 
Therefore, in the present randomized and placebo-controlled investigation (Figure 1), 125 
patients received either a single low dose treatment of BH4 (5 mg/kg [BH4-5]; n=17) or a 126 
high dose BH4 treatment (20 mg/kg [BH4-20]; n=12). On a separate day, a 127 
demographically matched subset of patients from each treatment group were re-tested 128 
following ingestion of a placebo (PLC; n=9). All participants reported to the Laboratory 129 
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of Integrated Vascular and Exercise Physiology (LIVEP) at the Georgia Prevention 130 
Institute on two separate occasions: a preliminary day and an experimental day. The 131 
preliminary day consisted of the informed consent process, body composition 132 
assessments, and a baseline pulmonary function test. For the experimental days, 133 
participants were asked to come to the LIVEP at 8 AM following an overnight fast, and 134 
having abstained from moderate to vigorous physical activity for 24 hours prior to 135 
arrival. All patients were instructed to adhere to the timing of their daily pulmonary 136 
therapy and come to the lab following their morning airway clearance treatments and 137 
inhaled medicines. Upon arrival to the LIVEP, vascular endothelial function was 138 
assessed in both patients and controls at baseline (Pre) followed by a venous blood 139 
draw. Then, patients received a treatment with either BH4-5 or BH4-20 (KUVAN®, 140 
BioMarin Pharmaceutical Inc. Novato, CA) dissolved in 120 ml of apple juice or a PLC 141 
was administered. Three hours following treatment (Post), another blood sample was 142 
obtained and vascular endothelial function was re-evaluated. The post-measurement 143 
time point was chosen based on previous studies indicating that the peak plasma BH4 144 
concentration occurs around 3 hours (7). All treatments were dispensed by the Augusta 145 
University Research Pharmacy. The details of the series were unknown by any of the 146 
investigators or patients involved in the study.   147 
 148 
Participant Characteristics and Clinical Laboratory Values.  Participant testing included 149 
standard anthropometric assessments of height, weight, calculation of body mass index 150 
(BMI; kg/m2), and resting systolic and diastolic blood pressures. Oxygen saturation was 151 
obtained at rest using an Onyx II fingertip sensor (Nonin Medical, Plymouth, MN). 152 
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Fasting concentrations of total cholesterol (TC), high-density lipoproteins (HDL), low-153 
density lipoproteins (LDL), triglycerides (TRIG), and glucose were obtained using a 154 
Cholestech LDX point of care analyzer (Alere Inc., Scarborough, ME). Concentrations of 155 
high sensitivity C-reactive protein (CRP) were determined using standard clinical core 156 
laboratory techniques (Laboratory Corporation of America Holdings, Burlington, NC). 157 
  158 
Pulmonary Function Testing (PFT). Pulmonary function testing was performed using 159 
closed circuit spirometry (ParvoMedics, Sandy, UT) to determine forced vital capacity 160 
(FVC), forced expiratory volume in one second (FEV1), FVC/FEV1 and forced expiratory 161 
flow (FEF25-75) according to the American Thoracic Society standards(1).  A minimum of 162 
three reproducible trials were completed by each participant and the best of three 163 
acceptable forced expiratory maneuvers was selected to represent the pulmonary 164 
function values.  The percent predicted data set was determined following spirometric 165 
reference standards(26). 166 
 167 
Endothelial Function.  Endothelial function was assessed via the brachial artery flow-168 
mediated dilation (FMD) test in accordance with the tutorial on the ultrasound 169 
assessment of FMD (12). Briefly, using a 12 MHz linear transducer, simultaneous B-170 
mode and blood velocity profiles (duplex mode) of the brachial artery were obtained 171 
(Logiq 7, GE Medical Systems, Milwaukee, WI).  A forearm occlusion cuff (D.E. 172 
Hokanson, Bellevue, WA), placed immediately distal to the medial epicondyle, was 173 
rapidly inflated to 250 mm Hg for 5 minutes (E-20 rapid cuff inflator, D.E. Hokanson, 174 
Bellevue, WA) to induce arterial occlusion and subsequent reactive hyperemia of the 175 
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brachial artery. R-wave gaiting (Accusync 72, Accusync Medical Research Corporation, 176 
Milford, CN) was utilized to capture end-diastolic arterial diameters for automated offline 177 
analysis of brachial artery vasodilation (Medical Imaging Applications, Coralville, Iowa).  178 
Hyperemic diameter and blood velocity were recorded every 4 seconds for the first 20 179 
seconds and every 5 seconds for the remainder of the 2 minute collection period.  Peak 180 
diameter was determined by the highest 5 second average following cuff release 181 
according to recommendations(12).  FMD is expressed as a percent increase in peak 182 
diameter from baseline diameter. Cumulative shear rate (area under the curve, s-1, 183 
AUC) was determined using the trapezoidal rule, every four seconds for the first 20 184 
seconds following cuff release, and every 5 seconds thereafter for the remainder of the 185 
2 minute data collection period.  186 
 187 
Cultured Endothelial Cells 188 
     To assess if treatment improved NOS coupling, cultured endothelial cells were 189 
incubated with a subset of patients (n=6) plasma before and following BH4-20 treatment 190 
and superoxide and NO production were measured fluorometrically.  Cryopreserved 191 
human aortic endothelial cells (HAoEC) were purchased from PromoCell (Heidelberg, 192 
Germany) and cultured on tissue culture-treated dishes (Corning Inc., Corning, NY) at 193 
37°C in 5% CO2 and 95% humidity. The recommended culture medium used was 194 
endothelial cell growth medium (ECGM) MV2 (PromoCell) supplemented with 0.05 195 
ml/ml heat-inactivated fetal calf serum, 5 ng/ml epidermal growth factor, 10 ng/ml basic 196 
fibroblast growth factor, 20 ng/ml insulin-like growth factor, 0.5 ng/ml of vascular 197 
endothelial growth factor 165, 1 μg/ml of ascorbic acid, 0.2 μg/ml of hydrocortisone 198 
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(PromoCell) and 1% penicillin/streptomycin (ThermoFisher, Waltham, MA). Cells were 199 
not used beyond passage six and allowed to reach confluence before experiments.  200 
 201 
In vitro Assessment of Uncoupled NOS 202 
     To investigate mechanisms related to the change in FMD, HAoEC were cultured in 203 
24-well plates (100,000 cells per well) for 24 hrs at 37°C in 5% CO2 environment.  After 204 
cells were grown to 60-70 % confluency, they were then incubated for ~16h in ECGM-205 
MV2 medium supplemented with 20% (v/v) plasma taken before and after BH4-20 206 
treatment from a subset of patients with CF (n=6).  After incubation, superoxide and NO 207 
levels were assessed using the fluorescent probes dihydroethidium (DHE) and 4,5-208 
Diaminofluorescein  diacetate (DAF-2A), respectively.  Briefly, cells were washed two 209 
times with PBS 1X then stimulated with angiotensin II (100 nM) for superoxide 210 
measurements or methacholine (100 μM) for assessment of NO production.  Cells were 211 
then treated with either DHE (10 μM, Sigma) or DAF-2A (10 μM, EMD Millipore) and 212 
incubated for 30 minutes at 37°C for detection of superoxide and NO, respectively.  To 213 
confirm specificity of signal detection, additional cells were pretreated with the 214 
superoxide dismutase mimetic tempol (100 nM, Sigma) or the nonselective NOS 215 
inhibitor L-nitroarginine methyl ester (L-NAME, 1mM, Sigma) for 30 minutes at 37°C 216 
prior to stimulation and fluorescent probe application.  All treatments were performed in 217 
duplicate and reported as averaged values.  4-5 pictures were taken for each 218 
well/treatment using Zeiss 780 Inverted Confocal microscope at 100X magnification (for 219 
DHE excitation/emission maxima were 510/595 nm and for DAF-2A excitation/emission 220 
maxima were 495/515 nm). The intensity of florescence was assessed using image J- 221 
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NIH software and was corrected to mm2.   All cell experiments were completed within 222 
the same time of day, minimizing the potential confounding effects of diurnal variation. 223 
 224 
Statistical Analyses.  225 
The sample size was computed for detecting a significant difference in the change in 226 
FMD% from Pre- to Post-BH4 treatment based on our previous study that examined the 227 
acute effect of BH4 in another clinical population(29). We found that the change in 228 
FMD% following BH4 treatment was 2.1 ± 2.3% which yielded a sample size of 12 at a 229 
significance level 0.05 with a power of 0.85.  230 
 231 
Values are presented as mean ± SD unless otherwise noted. Differences in patient 232 
characteristics between groups were determined using independent groups t-tests or 233 
analysis of variance (ANOVA). Primary analysis for group differences in the FMD 234 
response following treatment was performed using repeated-measures ANOVA or 235 
analysis of covariance (ANCOVA) to adjust for baseline measures and to provide an 236 
unbiased estimate of the mean group difference. Bonferroni correction was used for 237 
post-hoc analysis when a significant main effect was found. Paired t-tests were used to 238 
compare DHE and DAF pre and post BH4-20 treatment. Effect sizes for FMD responses 239 
after treatment are reported by Cohen's d values to represent small (d=0.2), medium 240 
(d=0.5), and large effect sizes (d=0.8) (4). An alpha <0.05 was considered statistically 241 
significant for all analyses. All analyses were performed using SPSS version 24.0 (IBM 242 
Corporation, Somers, NY).  243 
  244 
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RESULTS 245 
Participants Characteristics  246 
Demographic and clinical characteristics of patients with CF and healthy controls are 247 
presented in Table 1. Importantly, no significant differences were observed between 248 
patient groups for any demographics, pulmonary function, or blood chemistry values (all 249 
p>0.05). In addition, the pulmonary function variables represent a relatively healthy 250 
patient cohort with mild to moderate disease severity (8). Some indices of lung function 251 
as well as diastolic blood pressure, however, were significantly higher (p>0.05) in 252 
controls compared to the patients. Although all blood chemistry variables were within 253 
normal ranges, CRP was lower (p=0.003) and HDL was higher (p=0.003) in controls 254 
compared to patients.    255 
 256 
Basal Endothelial Function between CF Patients and Controls 257 
The average baseline FMD of all patients combined (n=29) was significantly lower 258 
compared with the demographically matched healthy control cohort (5.7 ± 3.4% vs. 8.4 259 
± 3.5% respectively, p = 0.005). In addition, the absolute change in artery diameter was 260 
greater in controls (0.17 ± 0.01 vs. 0.26 ± 0.01cm, p=0.001) while baseline diameter 261 
(0.31 ± 0.05 vs. 0.30 ± 0.05 cm, p=0.599), peak diameter (0.32 ± 0.05 vs. 0.33 ± 0.05 262 
cm, p=0.536), shear rate (55698 ± 27878 vs. 46971 ± 12444 s-¹,AUC, p=0.129), and 263 
TTP (53 ± 23 vs. 43 ± 18 sec, p=0.086) were all similar between patients and healthy 264 
controls.  265 
 266 
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Effect of BH4 on Endothelial Function in Patients with CF 267 
Pre- and post-treatment parameters of the FMD test following BH4-5, BH4-20 and PLC 268 
are presented in Table 2. Importantly, pre- and post- shear rates following treatment 269 
with BH4-5, BH4-20 or PLC were all similar (p=0.143, p=0.517, and p=0.132, 270 
respectively).  271 
All pre-treatment FMD parameters were similar between the three groups (all p>0.05). A 272 
significant treatment by time interaction for FMD (F(2, 33)=7.51, p=0.017) was observed 273 
when controlling for pre-treatment values. Specifically, Figure 2 illustrates a significantly 274 
greater change in FMD following BH4-20 treatment (1.1 ± 1.4 %, p = 0.023; d=0.33), 275 
whereas no change was observed with either BH4-5 (-0.51 ± 2.53 %, p = 0.132; d=0.16) 276 
or PLC (-0.84 ± 0.02, p = 0.273; d = 0.45).  277 
Similarly, there was a significant treatment by time interaction for peak diameter (cm) 278 
(F(2,34)=6.926, p=0.003). While there was a trend for an increase in peak diameter 279 
following BH4-20 (0.004 ± 0.007 cm, p=0.056), it decreased following PLC and BH4-5 280 
(0.005 ± 0.009 and -0.005 ± 0.007 cm, p=0.049 and 0.004 respectively). In addition, 281 
there was a significant treatment by time interaction for time to peak vasodilation (TTP; 282 
s) (F(2,34)=4.594, p=0.017). Specifically, no change was observed following BH4-5 (-3.8 ± 283 
24.7 s, p=0.574) or BH4-20 (5.0 ± 17.5 s, p=0.537); however, a significant decrease was 284 
observed following PLC (-32.5 ± 43.34 p=0.002). No difference (p>0.05) in blood 285 
pressure was observed between baseline and post treatment, respectively, following 286 
BH4-5 (SBP 108 ± 7 vs. 111 ± 6 mm Hg; DBP 61 ± 7 vs. 62 ± 8 mm Hg) and BH4-20 287 
(SBP 112 ± 15 vs. 111 ± 11 mm Hg; DBP 61 ± 8 vs. 61 ± 7 mm Hg). 288 
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No significant differences in baseline artery diameter (cm) (F(2, 34)=1.874, p=0.169), 289 
shear rate (s-¹,AUC) (F(2, 34)=1.545, p=0.228), or absolute change in diameter (cm) (F(2, 290 
34)=2.32, p=0.114) were observed. In addition, no significant relationships were 291 
observed between baseline FEV1 and the change in FMD either from BH4-5 (r=0.066; 292 
p=0.801) or BH4-20 (r=0.092; p=0.776).  293 
 294 
Endothelial Cell Coupling of NOS3 295 
Stimulated superoxide production was significantly lower (p=0.01) in endothelial cells 296 
pre-incubated with post BH4-20 plasma compared to endothelial cells treated with pre-297 
treatment plasma (Figure 3A). Inhibition of NOS (using L-NAME) significantly (p<0.001) 298 
attenuated stimulated superoxide production in cells treated with plasma prior to BH4-20 299 
treatment (Figure 3A).  NOS inhibition had no significant (p=0.065) effect on superoxide 300 
production in cells incubated with plasma post-BH4-20.  Specificity of stimulated DHE 301 
fluorescence for superoxide was confirmed with tempol (Figure 3A). Consistent with the 302 
above, stimulated NO production tended to be greater (p=0.10) in endothelial cells 303 
incubated with post BH4-20 plasma compared to incubation with pre-BH4-20 plasma, 304 
although this did not reach statistical significance.  Pre-incubation with the NOS inhibitor 305 
L-NAME confirmed NOS-mediated NO production (Figure 3B).  306 
 307 
 308 
 309 
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DISCUSSION 310 
Patients with CF exhibit systemic vascular endothelial dysfunction (24, 30); 311 
however, the mechanisms have yet to be elucidated. The present study sought to test 312 
the hypothesis that an acute treatment with BH4 would improve vascular endothelial 313 
function in patients with CF. For the first time, findings from the present study 314 
demonstrate that a single dose of 20 mg/kg of BH4 improves endothelial function in 315 
patients with CF that is accompanied by a decrease in NOS-mediated superoxide 316 
production, suggesting an improvement in NOS coupling.  In contrast, no change in 317 
endothelial function was observed following PLC or 5 mg/kg of BH4. Our proof of 318 
concept findings support the importance of BH4 bioactivity as a potential mechanism 319 
that may, in part, be responsible for vascular endothelial dysfunction in patients with CF 320 
(24, 30).   321 
  322 
Endothelial Function in Patients with CF 323 
CF is caused by mutation of the CFTR gene that is expressed in a wide spectrum 324 
of cells including the vascular endothelium (27). Our group has previously provided 325 
evidence of both micro- and macro- vascular endothelial dysfunction in young patients 326 
with CF who presented with a relatively well-preserved spirometric function (24, 30). 327 
Importantly, the present cohort of patients also exhibit endothelial dysfunction when 328 
compared to a demographically matched healthy control group. Collectively, these 329 
findings not only suggest that CF-related systemic consequences may precede a 330 
marked decline in pulmonary function, but also indicate that endothelial dysfunction may 331 
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be an early indicator of systemic deterioration and/or clinical manifestation in patients 332 
with CF.  333 
BH4 Improves Vascular Endothelial Function in Patients with CF 334 
For the first time, the present study demonstrates that a single dose of BH4 can 335 
improve vascular endothelial function in patients with CF, evidenced by a 1.1 % 336 
absolute and a 17% relative increase in FMD following high dose treatment (Figure 2). 337 
The FMD test represents a bioassay of NO bioavailability and assessment of 338 
endothelial function.  Although apparently small in magnitude, a 1% absolute increase in 339 
FMD has been associated with a 10-13% reduction in risk of future cardiovascular 340 
events and all-cause mortality (17, 36).  In addition, this moderate improvement 341 
(Cohen’s d=0.33) in FMD may have significant implications for quality of life and survival 342 
in this patient population through the improvement in other systemic manifestations of 343 
CF, including exercise capacity.  Future studies are warranted to determine the 344 
therapeutic effect of chronic BH4 treatment on both FMD and exercise capacity in CF. 345 
The improvement in FMD observed in the present study is in line with previous 346 
studies that have demonstrated an increase in endothelial function following acute 347 
administration of oral BH4 in different populations that exhibit systemic oxidative stress 348 
(6, 18, 19, 32). Although the exact mechanisms by which oral BH4 treatment increases 349 
endothelial-dependent vasodilation in patients with CF are unclear, an increase in 350 
endothelial NO production associated with improved eNOS coupling is likely to play an 351 
important role. To support this hypothesis we performed in vitro studies examining the 352 
ability of BH4-treated patient plasma to modulate endothelial cell superoxide and NO 353 
production (Figure 3).  Findings from this cell culture experiment suggest an 354 
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improvement in NOS coupling and subsequent NOS-mediated NO production in 355 
endothelial cells following BH4-20 treatment.  Importantly, the change in FMD observed 356 
following treatment in the present study was independent of basal lung function. Conduit 357 
artery FMD is shown to be primarily mediated by endothelial-derived NO (20), and BH4 358 
is a cofactor specific for eNOS that modulates NO synthesis in the vascular endothelium 359 
(3). In fact, previous studies have demonstrated that BH4 is able to increase NO 360 
bioavailability (5, 15) and promote vasodilation without impacting endothelial-361 
independent vasodilatory mechanisms (18, 25). Moreover, results from animal studies 362 
demonstrate that deficiency of endothelial BH4 alone is sufficient to cause vascular 363 
dysfunction even in the absence of atherogenic vascular disease (3).  Collectively, 364 
findings from the present study support the idea that insufficient bioactivity of BH4 in the 365 
endothelium contributes to endothelial dysfunction in CF (24). Although speculative, CF-366 
associated BH4 oxidation by overproduction of vascular reactive oxidative species may 367 
lead to decreased endothelial BH4 bioavailability, which in turn may uncouple eNOS and 368 
lead to a reduction in NO-mediated vasodilation. Impaired NO-dependent vasodilation 369 
can impair blood flow regulation during exercise especially under conditions of elevated 370 
basal oxidative stress.  Exercise intolerance is an independent contributor of mortality in 371 
CF. Therefore, understanding the mechanisms that contribute to vascular dysfunction in 372 
CF may have important clinical implications, and future studies are certainly needed to 373 
examine the mechanistic role of BH4 on NO generation and the development of 374 
vascular dysfunction in CF.  375 
A High Dose of BH4 may be Needed to Improve Endothelial Function in Patients 376 
with CF 377 
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Enteral administration of BH4, although unrelated to its vascular benefit, is 378 
clinically indicated to treat phenylketonuria using a dose between 5-20 mg/kg. This wide 379 
dosing range depends on 1) varying responsiveness related to genotype, 2) absorption, 380 
and/or 3) metabolic states of BH4 (23). Perhaps unsurprisingly, even the vascular effects 381 
following oral administration of BH4 appear to be complex and dose dependent (5, 23). 382 
In the present study, we observed an improvement in vascular endothelial function only 383 
following oral administration of BH4 at a dose of 20 mg/kg; PLC or 5 mg/kg of BH4 did 384 
not alter the FMD response. In support, prevailing data in the literature have already 385 
suggested a similar dose-dependent effect of BH4 on the vasculature (21, 23, 25). A 386 
daily dose of at least 400 mg of oral BH4 significantly improves endothelial function in 387 
patients with hypertension, whereas no effect was observed following a daily dose of 388 
200 mg(25). The average amount of BH4 given to the BH4-5 group in the present study 389 
was 265 ± 72 mg, which was similar to the previously demonstrated ineffective dose(25) 390 
and may explain the null response.  391 
A classic feature of CF is elevated systemic oxidative stress (9). In addition, BH4 392 
is easily oxidized by excessive free radicals. Therefore, a higher dose of BH4 may have 393 
been needed to balance multiple modulators of the eNOS uncoupling cascade, such as 394 
BH4 oxidation status, BH4 clearance rate, and the ratio of BH4 to BH2 in the vascular 395 
endothelium. Moreover, the progressive dose escalation designs that are often 396 
performed during early stages of clinical trials with BH4 supplementation (28) suggests 397 
the importance of disease-specific investigation for the sake of safety and efficacy of the 398 
use of BH4 in clinical populations. Although it is uncertain whether the BH4-associated 399 
improvement in endothelial function can be maintained with chronic BH4 administration 400 
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in patients with CF, further investigation is warranted to explore effective strategies for 401 
maintenance of adequate levels of intracellular BH4 bioavailability in patients with CF. 402 
Nonetheless, the present study demonstrates that a treatment dose of 20 mg/kg of BH4 403 
produces a significant increase in endothelial dependent vasodilation that is 404 
accompanied by an improved NOS3 coupling in patients with CF.  405 
 406 
Clinical Significance 407 
     Vascular endothelial dysfunction plays an important detrimental role in many 408 
pathological conditions. With respect to patients with CF, vascular dysfunction is a 409 
contributor to  exercise intolerance (24), a predictor of mortality that is independent of 410 
lung function in this patient population (22). Improvements in both endothelial function 411 
and NOS3 coupling following BH4 treatment observed in the present study may 412 
increase longevity of these patients due to 1) the overall improvement in cardiovascular 413 
disease risk, and 2) directly or indirectly increasing blood flow regulation and 414 
contributing to an improvement in exercise capacity.  Although both scenarios will have 415 
significant clinical implications on survival in patients with CF, further research is 416 
warranted to test these hypothesis. 417 
 418 
Conclusion 419 
For the first time, the present study has shown that a single oral dose of 20 mg/kg of 420 
BH4 significantly improved vascular endothelial function in patients with CF. The 421 
improvement in FMD was also accompanied by a significant decrease in endothelial cell 422 
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NOS-mediated superoxide production and an increase in NO supporting an 423 
improvement in NOS  coupling with BH4 treatment.  These findings indicates an 424 
important role of BH4 bioactivity in the regulation of endothelial dependent vasodilation 425 
in CF. Further studies are needed to investigate the ultimate translational potential of 426 
BH4 in prevention and treatment of vascular dysfunction in patients with CF.  427 
  428 
Competing Interests 429 
None to declare. 430 
 431 
Funding 432 
Supported in part by BioMarin Pharmaceutical Inc. (R.A.H.), American Heart 433 
Association (10SDG305006 to R.A.H.) and the Child Health Discovery Institute (R.A.H.).   434 
  435 
Downloaded from www.physiology.org/journal/jappl by ${individualUser.givenNames} ${individualUser.surname} (158.093.006.013) on November 16, 2018.
 Copyright © 2018, Journal of Applied Physiology. All rights reserved. 
Page | 21 
 
REFERENCE 436 
 437 
1. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J 438 
Respir Crit Care Med 152: 1107-1136, 1995. 439 
2. Alp NJ, and Channon KM. Regulation of endothelial nitric oxide synthase by 440 
tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 24: 413-420, 441 
2004. 442 
3. Chuaiphichai S, Crabtree MJ, McNeill E, Hale AB, Trelfa L, Channon KM, 443 
and Douglas G. A key role for tetrahydrobiopterin-dependent endothelial NOS 444 
regulation in resistance arteries: studies in endothelial cell tetrahydrobiopterin-deficient 445 
mice. Br J Pharmacol 174: 657-671, 2017. 446 
4. Cohen J. Eta-squared and partial eta-squared in fixed factor ANOVA designs. 447 
Educational and psychological measurement 33: 107-112, 1973. 448 
5. Cunnington C, Van Assche T, Shirodaria C, Kylintireas I, Lindsay AC, Lee 449 
JM, Antoniades C, Margaritis M, Lee R, Cerrato R, Crabtree MJ, Francis JM, 450 
Sayeed R, Ratnatunga C, Pillai R, Choudhury RP, Neubauer S, and Channon KM. 451 
Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment 452 
in patients with coronary artery disease. Circulation 125: 1356-1366, 2012. 453 
6. Eskurza I, Myerburgh LA, Kahn ZD, and Seals DR. Tetrahydrobiopterin 454 
augments endothelium-dependent dilatation in sedentary but not in habitually exercising 455 
older adults. J Physiol 568: 1057-1065, 2005. 456 
7. Fiege B, Ballhausen D, Kierat L, Leimbacher W, Goriounov D, Schircks B, 457 
Thony B, and Blau N. Plasma tetrahydrobiopterin and its pharmacokinetic following 458 
oral administration. Mol Genet Metab 81: 45-51, 2004. 459 
8. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Jr., Willey-460 
Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, 461 
Hazle L, Sabadosa K, Marshall B, and Cystic Fibrosis Foundation PTC. Cystic 462 
fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J 463 
Respir Crit Care Med 176: 957-969, 2007. 464 
9. Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, Iuliano L, 465 
Piroddi M, Dechecchi MC, Cabrini G, and Working Group on Inflammation in 466 
Cystic F. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim Biophys 467 
Acta 1822: 690-713, 2012. 468 
10. Green D. Point: Flow-mediated dilation does reflect nitric oxide-mediated 469 
endothelial function. J Appl Physiol (1985) 99: 1233-1234; discussion 1237-1238, 2005. 470 
11. Gruet M, Troosters T, and Verges S. Peripheral muscle abnormalities in cystic 471 
fibrosis: Etiology, clinical implications and response to therapeutic interventions. J Cyst 472 
Fibros 16: 538-552, 2017. 473 
12. Harris RA, Nishiyama SK, Wray DW, and Richardson RS. Ultrasound 474 
assessment of flow-mediated dilation. Hypertension 55: 1075-1085, 2010. 475 
13. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, Meinertz 476 
T, and Munzel T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in 477 
chronic smokers : evidence for a dysfunctional nitric oxide synthase. Circ Res 86: E36-478 
41, 2000. 479 
Downloaded from www.physiology.org/journal/jappl by ${individualUser.givenNames} ${individualUser.surname} (158.093.006.013) on November 16, 2018.
 Copyright © 2018, Journal of Applied Physiology. All rights reserved. 
Page | 22 
 
14. Heitzer T, Krohn K, Albers S, and Meinertz T. Tetrahydrobiopterin improves 480 
endothelium-dependent vasodilation by increasing nitric oxide activity in patients with 481 
Type II diabetes mellitus. Diabetologia 43: 1435-1438, 2000. 482 
15. Higashi Y, Sasaki S, Nakagawa K, Kimura M, Noma K, Hara K, Jitsuiki D, 483 
Goto C, Oshima T, Chayama K, and Yoshizumi M. Tetrahydrobiopterin improves 484 
aging-related impairment of endothelium-dependent vasodilation through increase in 485 
nitric oxide production. Atherosclerosis 186: 390-395, 2006. 486 
16. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a 487 
historical overview. J Physiol Pharmacol 53: 503-514, 2002. 488 
17. Inaba Y, Chen JA, and Bergmann SR. Prediction of future cardiovascular 489 
outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J 490 
Cardiovasc Imaging 26: 631-640, 2010. 491 
18. Machin DR, Clifton HL, Richardson RS, Wray DW, Donato AJ, and Frech 492 
TM. Acute oral tetrahydrobiopterin administration ameliorates endothelial dysfunction in 493 
systemic sclerosis. Clin Exp Rheumatol 35 Suppl 106: 167-172, 2017. 494 
19. Maki-Petaja KM, Day L, Cheriyan J, Hall FC, Ostor AJ, Shenker N, and 495 
Wilkinson IB. Tetrahydrobiopterin Supplementation Improves Endothelial Function But 496 
Does Not Alter Aortic Stiffness in Patients With Rheumatoid Arthritis. J Am Heart Assoc 497 
5: 2016. 498 
20. Mullen MJ, Kharbanda RK, Cross J, Donald AE, Taylor M, Vallance P, 499 
Deanfield JE, and MacAllister RJ. Heterogenous nature of flow-mediated dilatation in 500 
human conduit arteries in vivo: relevance to endothelial dysfunction in 501 
hypercholesterolemia. Circ Res 88: 145-151, 2001. 502 
21. Nielsen JB, Nielsen KE, and Guttler F. Tetrahydrobiopterin responsiveness 503 
after extended loading test of 12 Danish PKU patients with the Y414C mutation. J 504 
Inherit Metab Dis 33: 9-16, 2010. 505 
22. Nixon PA, Orenstein DM, Kelsey SF, and Doershuk CF. The prognostic value 506 
of exercise testing in patients with cystic fibrosis. N Engl J Med 327: 1785-1788, 1992. 507 
23. Pey AL, Perez B, Desviat LR, Martinez MA, Aguado C, Erlandsen H, Gamez 508 
A, Stevens RC, Thorolfsson M, Ugarte M, and Martinez A. Mechanisms underlying 509 
responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum Mutat 24: 510 
388-399, 2004. 511 
24. Poore S, Berry B, Eidson D, McKie K, and Harris R. Evidence of vascular 512 
endothelial dysfunction in young patients with cystic fibrosis. Chest 143: 939-945, 2013. 513 
25. Porkert M, Sher S, Reddy U, Cheema F, Niessner C, Kolm P, Jones DP, 514 
Hooper C, Taylor WR, Harrison D, and Quyyumi AA. Tetrahydrobiopterin: a novel 515 
antihypertensive therapy. J Hum Hypertens 22: 401-407, 2008. 516 
26. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, 517 
Hankinson JL, Ip MS, Zheng J, Stocks J, and Initiative ERSGLF. Multi-ethnic 518 
reference values for spirometry for the 3-95-yr age range: the global lung function 2012 519 
equations. Eur Respir J 40: 1324-1343, 2012. 520 
27. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, 521 
Zielenski J, Lok S, Plavsic N, Chou JL, and et al. Identification of the cystic fibrosis 522 
gene: cloning and characterization of complementary DNA. Science 245: 1066-1073, 523 
1989. 524 
Downloaded from www.physiology.org/journal/jappl by ${individualUser.givenNames} ${individualUser.surname} (158.093.006.013) on November 16, 2018.
 Copyright © 2018, Journal of Applied Physiology. All rights reserved. 
Page | 23 
 
28. Robbins IM, Hemnes AR, Gibbs JS, Christman BW, Howard L, Meehan S, 525 
Cabrita I, Gonzalez R, Oyler T, Zhao L, Du RH, Mendes LA, and Wilkins MR. Safety 526 
of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp 527 
Lung Res 37: 26-34, 2011. 528 
29. Rodriguez-Miguelez P, Gregg J, Seigler N, Bass L, Thomas J, Pollock JS, 529 
Sullivan JC, Dillard TA, and Harris RA. Acute Tetrahydrobiopterin Improves 530 
Endothelial Function in Patients with COPD. Chest 2018. 531 
30. Rodriguez-Miguelez P, Thomas J, Seigler N, Crandall R, McKie KT, Forseen 532 
C, and Harris RA. Evidence of microvascular dysfunction in patients with cystic fibrosis. 533 
Am J Physiol Heart Circ Physiol 310: H1479-1485, 2016. 534 
31. Rowe SM, Miller S, and Sorscher EJ. Cystic fibrosis. N Engl J Med 352: 1992-535 
2001, 2005. 536 
32. Taylor BA, Zaleski AL, Dornelas EA, and Thompson PD. The impact of 537 
tetrahydrobiopterin administration on endothelial function before and after smoking 538 
cessation in chronic smokers. Hypertens Res 39: 144-150, 2016. 539 
33. Thony B, Auerbach G, and Blau N. Tetrahydrobiopterin biosynthesis, 540 
regeneration and functions. Biochem J 347 Pt 1: 1-16, 2000. 541 
34. Tousson A, Van Tine BA, Naren AP, Shaw GM, and Schwiebert LM. 542 
Characterization of CFTR expression and chloride channel activity in human endothelia. 543 
Am J Physiol 275: C1555-1564, 1998. 544 
35. Tucker MA, Berry B, Seigler N, Davison GW, Quindry JC, Eidson D, McKie 545 
KT, and Harris RA. Blood flow regulation and oxidative stress during submaximal 546 
cycling exercise in patients with cystic fibrosis. J Cyst Fibros 2017. 547 
36. Xu Y, Arora RC, Hiebert BM, Lerner B, Szwajcer A, McDonald K, Rigatto C, 548 
Komenda P, Sood MM, and Tangri N. Non-invasive endothelial function testing and 549 
the risk of adverse outcomes: a systematic review and meta-analysis. Eur Heart J 550 
Cardiovasc Imaging 15: 736-746, 2014. 551 
  552 
Downloaded from www.physiology.org/journal/jappl by ${individualUser.givenNames} ${individualUser.surname} (158.093.006.013) on November 16, 2018.
 Copyright © 2018, Journal of Applied Physiology. All rights reserved. 
Page | 24 
 
FIGURE LEGEND 553 
 554 
 555 
 556 
 557 
Figure 1. Study Flow Chart 558 
CF: cystic fibrosis, BH4-5: 5mg/kg of BH4, BH4-20: 20mg/kg of BH4, PLC: placebo 559 
 560 
 561 
Figure 2. The change (Δ) in FMD(%) following BH4-20 compared to BH4-5 or PLC in 562 
patients with CF. Values are means ± standard error. * Significant difference (p< 0.05) 563 
from both BH4-5 and PLC. 564 
 565 
 566 
Figure 3.  Stimulated human aortic endothelial cell production of superoxide (panel A) 567 
and nitric oxide (panel B) incubated with pre and post BH4-20 patient 568 
plasma.  Representative fluorescent images of cells under basal, L-NAME, and Tempol 569 
conditions for each probe are illustrated.  *Significant from basal pre BH4-570 
20.  †Significant from corresponding basal value.  #Significant from corresponding basal 571 
and pre BH4-20 L-NAME.   572 
  573 
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Table 1. Characteristics and laboratory values for patient treatment groups (BH4-4 and 574 
BH4-20) and healthy controls (CON). 575 
 BH4-5 BH4-20 CON p-value* 
N 17 12 29  
Demographic     
   Sex (M/F) 7/10 6/6 13/16  
   Age (yrs) 17 ± 7 19 ± 8 22 ± 9 0.182 
   Height (cm) 158 ± 14 162 ± 11 165 ± 13 0.170 
   Weight (kg) 53 ± 14 57 ± 14 62 ± 21 0.285 
   BMI (kg/m2) 20.8 ± 3.3 21.8 ± 3.8 22.1 ± 5.6 0.665 
   Body Fat (%) 22.2 ± 6.0 23.5 ± 4.1 22 ± 8.5 0.525 
   SBP (mm Hg) 109 ± 13 110 ± 11 113 ± 15 0.635 
   DBP (mm Hg) 60 ± 8 62 ± 8 68 ± 11 0.015* 
Pulmonary function     
   FVC (L) 3.7 ± 1.3 3.8 ± 1.2 3.9 ± 1.1 0.711 
   FEV1 (L) 2.8 ± 1.1 3.0 ± 1.1 3.3 ± 0.8 0.145 
   FEV1/FVC (%) 74 ± 8 78 ± 10 85 ± 7 0.001* 
   FEV1 (% predicted) 87 ± 18 88 ± 20 98 ± 13 0.059 
   FEF25-75 (L/s) 2.5 ± 1.3 2.9 ± 1.5 3.6 ± 1.1 0.011* 
Blood chemistry     
   CRP (mg/L) 2.3 ± 2.1 3.9 ± 3.5 0.9 ± 1.4 0.003* 
   TC (mg/dL) 133 ± 39 150 ± 37 158 ± 27 0.066 
   HDL (mg/dL) 43 ± 15 48 ± 19 62 ± 18 0.003* 
   LDL (mg/dL) 73 ± 28 78 ± 16 85 ± 24 0.194 
   TRIG (mg/dL) 96  ± 36 83  ± 22 76 ± 35 0.191 
   TC/HDL ratio 3.1 ± 1.0 3.3 ± 0.8 2.7 ± 0.8 0.165 
   Glucose (mg/dL) 93 ± 35 95 ± 19 88 ± 9 0.667 
Values are mean ± SD. BMI: Body Mass Index, SBP: Brachial Systolic Blood Pressure, 576 
DBP: Brachial Diastolic Blood Pressure, FVC: Forced Vital Capacity, FEV1: Forced 577 
Expiratory Volume in one second, FEF25-75: Forced Expiratory Flow at 25-75%, CRP: C-578 
Reactive Protein, TC: Total Cholesterol, HDL: High-density Lipoproteins, LDL: Low-579 
density Lipoproteins, TRIG: Triglycerides  580 
*Significant difference between healthy controls and both BH4-5 and BH4-20 (p<0.05).581 
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Table 2. Parameters of the FMD test in patients with CF before (Pre) and after (Post) treatment with 5 mg/kg of BH4 (BH4-582 
5), 20 mg/kg of BH4 (BH4-20), and placebo (PLC).  583 
Variable BH4-5 BH4-20    PLC
 Pre Post Pre  Post  Pre  Post  
Baseline diameter (cm) 0.31 ± 0.05 0.30 ± 0.05  0.30 ± 0.06  0.31 ± 0.06 0.33 ± 0.05 0.33 ± 0.05  
Peak diameter (cm) 0.32 ± 0.05 0.32 ± 0.06 0.32 ± 0.05 0.33 ± 0.06  0.35 ± 0.05 0.34 ± 0.05 
Shear rate (s-¹,AUC) 58269 ± 33110 49548 ± 29841 52056 ± 18949  54460 ± 23250 52527 ± 25003 43242 ± 30749 
Absolute change (cm)  0.016 ± 0.009 0.014 ± 0.007 0.018 ± 0.007 0.021 ± 0.006* 0.021 ± 0.012 0.018 ± 0.008 
FMD (%)  5.3 ± 3.5 4.8 ± 2.8 6.3 ± 3.2 7.4 ± 3.4* 6.5 ± 4.1 5.7 ± 2.7 
TTP (sec) 54.17 ± 33.16 47.50 ± 27.16 53.61 ± 21.33 59.72 ± 17.70 70.83 ± 35.26 41.39 ± 16.35* 
Values are mean ± SD. AUC: Area under a Curve, FMD: Flow-Mediated Dilation, TTP: Time-to-Peak.   584 
* Significant change from Pre-treatment values (p < 0.05) 585 
 586 
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